News

Combination of Three Tests Can Spot TTR-FAP Early, Study Reports

Cold and pinprick sensitivity in the hands and electrical impulse speed in nerves can help doctors make an early diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP), a study reports. The research, “Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis,” appeared in the journal Brain & Behavior. Transthyretin…

Inotersen Clinical Development Update Presented at Conference

Ionis Pharmaceuticals’ inotersen (IONIS-TTR Rx) continues to demonstrate sustained, long-term benefit for patients with familial amyloid polyneuropathy (FAP), also known as hereditary ATTR (hATTR) amyloidosis. Recent positive results of a study were the subject of several presentations at the 16th International Symposium on Amyloidosis (ISA) being held March…

Ionis and Akcea Partner to Market FAP Therapy Candidate Inotersen

Ionis Pharmaceuticals and its affiliate Akcea Therapeutics recently announced an exclusive worldwide license to commercialize inotersen and a follow-up therapy, AKCEA-TTR-LRx, formerly known as IONIS-TTR-LRx. Inotersen is a therapy candidate being evaluated for the treatment of familial amyloid polyneuropathy (FAP). In May 2017, Ionis announced positive results from…